Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Visceral leishmaniasis clinical management in endemic districts of India, Nepal, and bangladesh.

Banjara MR, Hirve S, Siddiqui NA, Kumar N, Kansal S, Huda MM, Das P, Rijal S, Gurung CK, Malaviya P, Arana B, Kroeger A, Mondal D.

J Trop Med. 2012;2012:126093. doi: 10.1155/2012/126093. Epub 2012 May 9.

2.

Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy.

Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, Siddhivinayak H, Kroeger A, Boelaert M.

PLoS Negl Trop Dis. 2009;3(1):e355. doi: 10.1371/journal.pntd.0000355. Epub 2009 Jan 13.

3.

Active case detection in national visceral leishmaniasis elimination programs in Bangladesh, India, and Nepal: feasibility, performance and costs.

Huda MM, Hirve S, Siddiqui NA, Malaviya P, Banjara MR, Das P, Kansal S, Gurung CK, Naznin E, Rijal S, Arana B, Kroeger A, Mondal D.

BMC Public Health. 2012 Nov 20;12:1001. doi: 10.1186/1471-2458-12-1001.

4.

How do health care providers deal with kala-azar in the Indian subcontinent?

Kumar N, Singh SP, Mondal D, Joshi A, Das P, Sundar S, Kroeger A, Hirve S, Siddiqui NA, Boelaert M.

Indian J Med Res. 2011 Sep;134:349-55.

5.

Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs.

Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, Mondal D, Sundar S, Das P, Gurung CK, Rijal S, Thakur CP, Varghese B, Kroeger A.

PLoS Negl Trop Dis. 2011 Feb 8;5(2):e960. doi: 10.1371/journal.pntd.0000960.

6.

Human resource assessment for scaling up VL active case detection in Bangladesh, India and Nepal.

Naznin E, Kroeger A, Siddiqui NA, Sundar S, Malaviya P, Mondal D, Huda MM, Das P, Karki P, Banjara MR, Dreesch N, Gedik G.

Trop Med Int Health. 2013 Jun;18(6):734-42. doi: 10.1111/tmi.12124. Epub 2013 May 8.

7.

Elimination of visceral leishmaniasis in Nepal: pipe-dreams and possibilities.

Joshi AB, Banjara MR, Pokhrel S, Jimba M, Singhasivanon P, Ashford RW.

Kathmandu Univ Med J (KUMJ). 2006 Oct-Dec;4(4):488-96.

PMID:
18603960
8.

Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal.

Hirve S, Singh SP, Kumar N, Banjara MR, Das P, Sundar S, Rijal S, Joshi A, Kroeger A, Varghese B, Thakur CP, Huda MM, Mondal D.

Am J Trop Med Hyg. 2010 Sep;83(3):507-11. doi: 10.4269/ajtmh.2010.09-0685.

9.

Can visceral leishmaniasis be eliminated from Asia?

Joshi A, Narain JP, Prasittisuk C, Bhatia R, Hashim G, Jorge A, Banjara M, Kroeger A.

J Vector Borne Dis. 2008 Jun;45(2):105-11. Review.

10.

Recent advances in the diagnosis and treatment of kala-azar.

Sundar S, Chakravarty J.

Natl Med J India. 2012 Mar-Apr;25(2):85-9. Review.

PMID:
22686715
11.

Visceral leishmaniasis in Nepal during 1980-2006.

Joshi DD, Sharma M, Bhandari S.

J Commun Dis. 2006 Mar;38(2):139-48.

PMID:
17370676
12.

Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.

Singh UK, Prasad R, Mishra OP, Jayswal BP.

Indian J Pediatr. 2006 Dec;73(12):1077-80.

PMID:
17202633
13.
14.

The economic impact of visceral leishmaniasis on households in Bangladesh.

Anoopa Sharma D, Bern C, Varghese B, Chowdhury R, Haque R, Ali M, Amann J, Ahluwalia IB, Wagatsuma Y, Breiman RF, Maguire JH, McFarland DA.

Trop Med Int Health. 2006 May;11(5):757-64. Erratum in: Trop Med Int Health. 2006 Sep;11(9):1482.

15.

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.

Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK.

J Infect Dis. 2007 Aug 15;196(4):591-8. Epub 2007 Jun 29.

16.

Will visceral leishmaniasis be eliminated from Nepal? A review of recent (1994-2006) control efforts.

Bhandari GP, Angdembe MR, Rijal S, Boelaert M.

Nepal Med Coll J. 2011 Sep;13(3):220-5. Review.

PMID:
22808821
17.

How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data.

Chowdhury R, Mondal D, Chowdhury V, Faria S, Alvar J, Nabi SG, Boelaert M, Dash AP.

PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3020. doi: 10.1371/journal.pntd.0003020. eCollection 2014 Aug.

18.

Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.

Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K.

Am J Trop Med Hyg. 2009 Apr;80(4):580-2.

19.

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ.

J Antimicrob Chemother. 2012 Nov;67(11):2576-97. doi: 10.1093/jac/dks275. Epub 2012 Jul 24. Review.

20.

Oral miltefosine for Indian visceral leishmaniasis.

Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.

N Engl J Med. 2002 Nov 28;347(22):1739-46.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk